The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 41.00
Ask: 42.00
Change: -2.00 (-4.60%)
Spread: 1.00 (2.439%)
Open: 43.50
High: 43.50
Low: 41.50
Prev. Close: 43.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio news – CamGraPhIC loan facility

24 Jul 2023 07:00

RNS Number : 8788G
Frontier IP Group plc
24 July 2023
 

RNS

AIM: FIPP

24 July 2023

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

Portfolio news - CamGraPhIC loan facility of up to £1.5 million

 

Frontier IP, a specialist in commercialising intellectual property, announces that its portfolio company, CamGraPhIC Limited ("CamGraphIC" or the "Company") has put in place a new loan facility which will provide funding of up to £1.5 million (the "Loan Notes") to enable CamGraphIC to accelerate the development of its growth.

 

A total of £1.043 million Loan Notes have been subscribed for under this the new loan note instrument. Frontier IP has subscribed for £1.0 million of Loan Notes pursuant to the loan facility comprising amounts that have been advanced by Frontier IP to CamGraphIC between 24 February 2023 and 21 July 2023.

 

The key terms of the Loan Notes are:

 

- up to £1,500,000 fixed rate 8% unsecured loan notes can be issued in the Company;

- the Loan Notes will bear interest at a rate of 8% per annum from the date of issue;

- the Loan Notes are redeemable by the Company (so far as not converted) on the date which is 12 months after completion of a fundraising in which the Company raises new equity of £1 million or more;

- the Loan Notes may be converted on a fundraising of any amount at the option of the noteholder and with the agreement of the Company; and

- if the Loan Notes are converted, the Company will be required to issue each noteholder with warrants to subscribe for new shares in the Company equivalent to 20% of the Loan Notes at the price at which the loan notes converted.

 

CamGraphIC is the Group's second graphene spin out from the University of Cambridge. The Company was formed to develop graphene-based photonics for high-speed data and telecommunications. Graphene photonics is seen by the Company's industrial partners as a key enabler for 5G technologies and has potential applications in a range of other sectors.

 

Separate to the loan facility detailed above, Frontier IP has also previously: (i) advanced amounts totalling £210,000 to CamGraphIC under previous loan agreements entered into in 2019 and 2020 to provide working capital for the Company; and (ii) subscribed for a total of £1.018 million loan notes under a loan instrument originally issued by CamGraphIC in June 2021, details of which were announced by Frontier IP on 8 July 2021.

 

As a consequence, as at the date of this announcement the total amount advanced by Frontier IP to CamGraphIC is £2.23 million. In addition, Frontier IP holds a 20.8 per cent. equity stake in CamGraphIC.

 

Proceeds from the funding will be used by CamGraphIC to continue development and scale up of its technology, as the Company works with a number of potential customers, including multinationals in the semiconductor and telecommunications sectors. In addition, CamGraPhIC is already providing revenue generating services to several major government and commercial organisations both commercially and via grant funded programmes.

 

 

ENQUIRIES

 

Frontier IP Group Plc

T: 020 3968 7815

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

T: 0203 328 5656

Singer Capital Markets (Broker)

Sandy Fraser / Harry Gooden / George Tzimas

 

T: 0207 496 3000

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

 

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFUEAEXDAEXDEAA
Date   Source Headline
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.